There are biomarkers in EVs that respond to the prognosis of prostate cancer, such as ACTN4 (α-coactinomycin 4), PD-L1 (programmed death receptor ligand 1), Integrin αvβ3 (Integrin αvβ3), and Del-1 (Developmental endothelial locus-1), which have been correlated with the poor prognosis of prostate cancer, therefore the prognosis of patients can be assessed by detecting EVs in serum. This evidence concerns the gene EDIL3 and prostate carcinoma.